Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 68, Issue 6, Pages 931-949Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-010-0525-1
Keywords
Nicotinic; Acetylcholine; Alpha7; Inflammation; Diabetes
Categories
Funding
- NHLBI NIH HHS [R01 HL094609] Funding Source: Medline
Ask authors/readers for more resources
In recent years the etiopathology of a number of debilitating diseases such as type 2 diabetes, arthritis, atherosclerosis, psoriasis, asthma, cystic fibrosis, sepsis, and ulcerative colitis has increasingly been linked to runaway cytokine-mediated inflammation. Cytokine-based therapeutic agents play a major role in the treatment of these diseases. However, the temporospatial changes in various cytokines are still poorly understood and attempts to date have focused on the inhibition of specific cytokines such as TNF-alpha. As an alternative approach, a number of preclinical studies have confirmed the therapeutic potential of targeting alpha7 nicotinic acetylcholine receptor-mediated anti-inflammatory effects through modulation of proinflammatory cytokines. This cholinergic anti-inflammatory pathway modulates the immune system through cholinergic mechanisms that act on alpha7 receptors expressed on macrophages and immune cells. If the preclinical findings translate into human efficacy this approach could potentially provide new therapies for treating a broad array of intractable diseases and conditions with inflammatory components.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available